Study finds new opioid use high among adults with COPD, raising safety concerns in this vulnerable population.
New opioid use was high among older people with chronic obstructive pulmonary disease (COPD) in community-dwelling adults and residents of long-term care facilities in Ontario, Canada, according to a study in the British Journal of Clinical Pharmacology.
Nicholas T. Vozoris, BSc, MHSc, MD, FRCPC, of St. Michael’s Hospital in Toronto, and colleagues said potential safety concerns are raised by the degree and pattern of new opioid use in this older and respiratory-vulnerable population. They also noted that several patterns potentially indicative of excessive opioid use were seen among older adults with COPD—especially among frailer long-term care residents.
The study followed 107,109 community-dwelling and 16,207 long-term care resident older adults with physician-diagnosed COPD from 2003 to 2012. During the observation period, 68.1% of community-dwelling and 54.4% of long-term care residents received an incident opioid drug. The investigators found patterns of new opioid use among older adults with COPD that have the potential to augment possible negative drug-related effects including multiple opioid dispensing (8.8%), dispensing for more than 30 days’ duration (up to 19.8%), second dispensing (35%-43%), and early refills (24.2%) were observed.
Incident opioid dispensing was also reported to occur during COPD exacerbations (6.9% among all long-term care residents; 18.1% among long-term care residents with frequent exacerbations). The same patterns of incident opioid use occurred among community-dwelling individuals but with lower frequencies, the study reported.
The majority of new opioid use during exacerbations occurred either on the day of hospital presentation or discharge or in the days following hospital discharge.
“Therefore, drug reconciliation during hospitalization may be a key process for optimizing opioid drug use in this population,” the investigators said. “The majority of opioid prescriptions in the present study population originated from family physicians, suggesting that they may play an important role in optimizing opioid drug use as well.”
Opioid prescribing for COPD patients might reflect physician intention to use multi-modal analgesic therapy to treat chronic musculoskeletal pain, a common problem in COPD, the investigators said, but they noted that several recent Cochrane reviews have concluded that there is minimal good-quality evidence supporting opioids as an effective treatment for chronic musculoskeletal pain. Further study is needed to assess potential respiratory-related health outcomes of opioid use among older adults with COPD.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More